Search
PROGEN PHARMACEUTICALS LIMITED (PGL)

PROGEN PHARMACEUTICALS LIMITED (PGL)

  Print

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!


General Information
Company Name: Progen Pharmaceuticals Limited
Stock Code: PGL
Website: www.progen-pharma.com
GICS Sub-Industry: Biotechnology
Market Cap ($M): 4
Equiv. Shares (M): 25

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
$ 0.170 $ 0.170 $ 0.170 $ 0.170 $ 0.170 500 0%

Company Overview

Business Description:
Progen Pharmaceuticals Limited (PGL) is a global biotechnology company involved in the discovery, research and development, and commercialisation of small molecule pharmaceuticals primarily for the treatment of cancer. PGL also provides contract services related to the process development, manufacture and quality assurance of biological products. PGL focus on two main development products, anti-angiogenesis and anti-metastatic products, both of which try to control tumor growth and spread.


Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2011  A -6.1 -24.7 -- 0.0 0.0 0.0 --
2010  A -15.8 -64.1 -- 0.0 0.0 0.0 --
2009  A -5.5 -10.0 -- 0.0 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2009 A 2010 F 2011 F 2009 A 2010 F 2011 F 2009 A 2010 F 2011 F
CSL (CSL) $16,069 M 0.0602 0.1144 0.0939 17.8226 15.9930 14.6205 0.0259 0.0280 0.0314
Mesoblast (MSB) $1,846 M -- -- -- -- 3270.0000 -- 0.0000 0.0000 0.0000
Progen Pharmaceuticals (PGL) $4 M -- -- -- -- -- -- 0.0000 -- --
Prima Biomed (PRR) $170 M -- -- -- -- -- -- 0.0000 -- --
Starpharma (SPL) $390 M -- -- -- -- -- -- 0.0000 0.0000 0.0000

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
PGL -- -- 0.47 -- 1.37
Market 1.29 11.1 1.08 1.59 2.71
Sector 0.78 17.2 2.25 1.58 6.01

Directors
Name Position Start Date
Mr Stuart Bruce James Chairman 01 July 2009
Mr Heng H Tang Non-Executive Director 17 July 2009
Dr Woei-Jia Jiang Non-Executive Director 16 June 2011

Management
Name Position
Susan MacLeman Chief Executive Officer
Laurence Marton Chief Scientific Officer
Fleur Lankesheer Director, Business Development and Legal
Michael Fitgerald Director, Clinical Operations US
Paul Dixon General Manager, Finance and Company Secretary

Substantial Shareholders
Holding Name
2,096,482 (8.48%) Medigen Biotechnology Corp.
1,243,251 (5.03%) CCH Investment Corp. and Tzu Liang Huang
2,122,781 (8.59%) Su-Hua Chuang

Calendar of Events
Date Event
28 November 2012 Report (Annual)
28 September 2012 Report (Annual)
21 August 2012 Report (Prelim)
20 February 2012 Report (Interim)
15 February 2012 Report (Interim)
Search for Managed Funds, Superannuation Funds and Retirement Funds Find a Managed Fund Reduce your fees and save money on your Managed Funds with our 100% Entry Fee Rebate 100% Entry Fee Rebate

Login
Email
Password
     Log me in automatically in future
Forgotten password? | Secure Login | Terms & Conditions
Free Membership

Membership benefits...

  • 100% entry fee rebates
  • Cash back on your managed fund investments with our innovative TrailCap™ program
  • Independent research on...
    • over 1,000 managed funds
    • over 300 ASX-listed Companies
    • top performing suburbs/postcodes
  • Access to IPOs/floats & other investment offers
  • Superior investment tools...
    • Portfolio manager
    • Watchlists
    • Alerts
  • Regular investment e-newsletter

Advertisement

Portfolio / Watchlist

Start a new portfolio / view your existing portfolio.
Track all your assets and manage your investments easily.

Trade Shares Online from $19.95^

eNewsletter

Keep up to date with new investments and important news - subscribe to our FREE weekly eNewsletters. Sign up now!

Free Guides

Financing your Investment Property

An educational booklet to help you learn the language of residential property financing with an introduction on how the tax system can help improve your cashflow.

More details...


News

Call to block Rinehart's board bid

The Age 3/02/2012 | HIGH-PROFILE director Geoffrey Cousins has called on major shareholders to block Gina Rinehart from gaining a board seat at Fairfax Media.

Call to block Rinehart's board bid

The Age 3/02/2012 | HIGH-PROFILE director Geoffrey Cousins has called on major shareholders to block Gina Rinehart from gaining a board seat at Fairfax Media.

Fairfax urged to beware boardroom influence

Sydney Morning Herald 3/02/2012 | THE Telstra director Geoffrey Cousins has called on large shareholders in Fairfax Media to block Gina Rinehart from gaining a board seat.

Call to block Rinehart's board bid

The Age 3/02/2012 | Geoffrey Cousins calls on major shareholders to block Gina Rinehart from gaining a board seat at Fairfax Media.

PMP lowers guidance

Sydney Morning Herald 3/02/2012 | The publisher and direct marketer PMP has cut its earnings guidance and implemented further restructuring because of poor trading conditions and weaker printing orders. The news sent shares to a two-year low, down 4?, or 8.3 per cent, at 44?. Print markets in both Australia and New Zealand have suffered with existing customers using the services less, and intense competition for new contracts resulting in lower margins. Earnings before interest and tax, and before significant items, are now ...

Hedge funds give big to 'Wall Street candidate'

The Age 2/02/2012 | Donor records reveal Romney campaign heavily backed by hedge fund managers.

More...


Sponsored Links

More from our network...